ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells

Journal of Cellular Physiology

Volumn 229, Issue 7, 2014, Pages 856-867

  Wang, Xuening ^a   Pesakhov, Stella ^b   Harrison, Jonathan S ^c   Danilenko, Michael ^b   Studzinski, George P ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CD11B ANTIGEN; CD14 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 7; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MEF2C; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL STRAIN U937; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MIDDLE AGED; MONOCYTIC DIFFERENTIATION; PHENOTYPE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANILINE COMPOUNDS; BENZODIAZEPINONES; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; INDOLES; LEUKEMIA, MYELOID; MEF2 TRANSCRIPTION FACTORS; MITOGEN-ACTIVATED PROTEIN KINASE 7; MONOCYTES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; U937 CELLS; VITAMIN D;

EID: 84896526361     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24513     Document Type: Article

References (62)

1. Alvarez-Fernandez S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, Burrows FJ, Esparis-Ogando A, Pandiella A. 2013. Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res 19:2677-2687.
2. Avruch J. 2007. MAP kinase pathways: The first twenty years. Biochim Biophys Acta 1773:1150-1160.
3. Breitman TR, Selonick SE, Collins SJ. 1980. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936-2940.
4. Buschbeck M, Hofbauer S, Di Croce L, Keri G, Ullrich A. 2005. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 6:63-69.
5. Caffrey DR, O'Neill LA, Shields DC. 1999. The evolution of the MAP kinase pathways: Coduplication of interacting proteins leads to new signaling cascades. J Mol Evol 49:567-582.
6. Carvajal-Vergara X, Tabera S, Montero JC, Esparis-Ogando A, Lopez-Perez R, Mateo G, Gutierrez N, Parmo-Cabanas M, Teixido J, San Miguel JF, Pandiella A. 2005. Multifunctional role of Erk5 in multiple myeloma. Blood 105:4492-4499.
7. Cavanaugh JE. 2004. Role of extracellular signal regulated kinase 5 in neuronal survival. Eur J Biochem 271:2056-2059.
8. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. 2003. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 17:1263-1293.
9. Charni S, Aguilo JI, Garaude J, de Bettignies G, Jacquet C, Hipskind RA, Singer D, Anel A, Villalba M. 2009. ERK5 knockdown generates mouse leukemia cells with low MHC class I levels that activate NK cells and block tumorigenesis. J Immunol 182:3398-3405.
10. Dennis VC, Albertson GL. 2006. Doxercalciferol treatment of secondary hyperparathyroidism. Ann Pharmacother 40:1955-1965.
11. Drew BA, Burow ME, Beckman BS. 2012. MEK5/ERK5 pathway: The first fifteen years. Biochim Biophys Acta 1825:37-48.
12. Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P, Pandiella A. 2002. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 22:270-285.
13. Friday BB, Adjei AA. 2008. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346.
14. Friend C, Zajac-Kaye M, Holland JG, Pogo BG. 1987. Depletion of sodium butyrate from the culture medium of Friend erythroleukemia cells undergoing differentiation. Cancer Res 47:378-382.
15. Garaude J, Cherni S, Kaminski S, Delepine E, Chable-Bessia C, Benkirane M, Borges J, Pandiella A, Iniguez MA, Fresno M, Hipskind RA, Villalba M. 2006. ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol 177:7607-7617.
16. Gaynor R, Simon K, Koeffler P. 1991. Expression of c-jun during macrophage differentiation of HL-60 cells. Blood 77:2618-2623.
17. Goyert SM, Ferrero E, Rettig WJ, Yenamandra AK, Obata F, Le Beau MM. 1988. The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science 239:497-500.
18. Grignani F, Fagioli M, Ferrucci PF, Alcalay M, Pelicci PG. 1993. The molecular genetics of acute promyelocytic leukemia. Blood Rev 7:87-93.
19. 3-induced monocytic differentiation of HL60 cells. Cancer Res 64:370-377.
20. Kamakura S, Moriguchi T, Nishida E. 1999. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274:26563-26571.
21. Kaspers GJ, Creutzig U. 2005. Pediatric acute myeloid leukemia: International progress and future directions. Leukemia 19:2025-2029.
22. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. 1997. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. Embo J 16:7054-7066.
23. Liu L, Cundiff P, Abel G, Wang Y, Faigle R, Sakagami H, Xu M, Xia Z. 2006. Extracellular signal-regulated kinase (ERK) 5 is necessary and sufficient to specify cortical neuronal fate. Proc Natl Acad Sci USA 103:9697-9702.
24. Lohle M, Hermann A, Glass H, Kempe A, Schwarz SC, Kim JB, Poulet C, Ravens U, Schwarz J, Scholer HR, Storch A. 2012. Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors. Stem Cells 30:570-579.
25. Marcinkowska E, Garay E, Gocek E, Chrobak A, Wang X, Studzinski GP. 2006. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1, 25-dihydroxyvitamin D3. Exp Cell Res 312:2054-2065.
26. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY. 2003. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22:1381-1389.
27. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Xiaolei G, Boga SB, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletire MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland G, Jayaraman L, Zawel L, Fawell SE, Samatar AA. 2013. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 3:742-750.
28. Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, Meyer C, Rosenwald A, Drexler HG, MacLeod RA. 2007. Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 109:3015-3023.
29. Natsuka S, Akira S, Nishio Y, Hashimoto S, Sugita T, Isshiki H, Kishimoto T. 1992. Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood 79:460-466.
30. Nishimoto S, Kusakabe M, Nishida E. 2005. Requirement of the MEK5-ERK5 pathway for neural differentiation in Xenopus embryonic development. EMBO Rep 6:1064-1069.
31. Pan Z, Hetherington CJ, Zhang DE. 1999. CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development. J Biol Chem 274:23242-23248.
32. Perez-Madrigal D, Finegan KG, Paramo B, Tournier C. 2012. The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell Signal 24:2360-2368.
33. Pierce GB, Jr. Verney EL. 1961. An in vitro and in vivo study of differentiation in teratocarcinomas. Cancer 14:1017-1029.
34. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. 1991. Phosphorylation of c-jun mediated by MAP kinases. Nature 353:670-674.
35. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. 1998. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18:4301-4314.
36. Razumovskaya E, Sun J, Ronnstrand L. 2011. Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD. Biochem Biophys Res Commun 412:307-312.
37. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. 2002. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA 99:9248-9253.
38. Roberts OL, Holmes K, Muller J, Cross DA, Cross MJ. 2009. ERK5 and the regulation of endothelial cell function. Biochem Soc Trans 37:1254-1259.
39. Roberts OL, Holmes K, Muller J, Cross DA, Cross MJ. 2010. ERK5 is required for VEGF-mediated survival and tubular morphogenesis of primary human microvascular endothelial cells. J Cell Sci 123:3189-3200.
40. Sachs L. 1978. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 274:535-539.
41. Santarpia L, Lippman SM, El-Naggar AK. 2012. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103-119.
42. Schubert D, Humphreys S, Jacob F, de Vitry F. 1971. Induced differentiation of a neuroblastoma. Dev Biol 25:514-546.
43. Schuler A, Schwieger M, Engelmann A, Weber K, Horn S, Muller U, Arnold MA, Olson EN, Stocking C. 2008. The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. Blood 111:4532-4541.
44. Sherman ML, Stone RM, Datta R, Bernstein SH, Kufe DW. 1990. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem 265:3320-3323.
45. Sohn SJ, Sarvis BK, Cado D, Winoto A. 2002. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277:43344-43351.
46. Song H, Jin X, Lin J. 2004. Stat3 upregulates MEK5 expression in human breast cancer cells. Oncogene 23:8301-8309.
47. Studzinski GP, Wang X, Ji Y, Wang Q, Zhang Y, Kutner A, Harrison JS. 2005. The rationale for deltanoids in therapy for myeloid leukemia: Role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 97:47-55.
48. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872.
49. Tatake RJ, O'Neill MM, Kennedy CA, Wayne AL, Jakes S, Wu D, Kugler SZ, Jr. Kashem MA, Kaplita P, Snow RJ. 2008. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun 377:120-125.
50. Wang Q, Wang X, Studzinski GP. 2003. Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1, 25-dihydroxyvitamin D3. J Cell Biochem 89:1087-1101.
51. Wang QF, Friedman AD. 2002. CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood 99:2776-2785.
52. 3. Cell Cycle 9:4542-4551.
53. 3-induced differentiation of HL60 cells. J Cell Biochem 80:471-482.
54. 3. Cancer Res 66:4402-4409.
55. Wang X, Tournier C. 2006. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 18:753-760.
56. Wang ZY, Chen Z. 2008. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505-2515.
57. Yan C, Luo H, Lee JD, Abe J, Berk BC. 2001. Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. J Biol Chem 276:10870-10878.
58. Yan L, Carr J, Ashby PR, Murry-Tait V, Thompson C, Arthur JS. 2003. Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev Biol 3:11.
59. Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR, III. Gray NS, Lee JD. 2010. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18:258-267.
60. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920.
61. 3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol Oncol 28:124-132.
62. Zhou G, Bao ZQ, Dixon JE. 1995. Components of a new human protein kinase signal transduction pathway. J Biol Chem 270:12665-12669.